Application of New Quinolone Antimicrobial Drug "Gatifloxacin Ophthalmic Solution" in the US
July 30, 2002
We are pleased to inform you that FDA approval for the new quinolone antimicrobial drug, "Gatifloxacin ophthalmic solution" created by Kyorin Pharmaceutical Co., Ltd. (Ikuo Ogihara, President) was applied for by our licensee, Allergan USA (D. Pyott, President) on May 30th.
Allergan highly values the excellent antimicrobial effect and high safety of Gatifloxacin while Kyorin highly values Allergan's unparalleled development and marketing capabilities in the ophthalmic field. As a result, a license agreement was concluded between these two companies in August 2000.
Since then, Allergan has taken the development initiative in the US. Allergan is scheduled to launch this product in 2003 and intends to grow this product into a major product in the market of antimicrobial ophthalmic solution in major countries, including the USA.
- Application of New Quinolone Antimicrobial Drug "Gatifloxacin Ophthalmic Solution" in the US [ PDF 7.2 KB ]
Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.